• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC).

作者信息

Tan Aaron C, Teh Yi Lin, Lai Gillianne G Y, Tan Daniel S W

机构信息

a Division of Medical Oncology , National Cancer Centre Singapore , Singapore , Singapore.

出版信息

Expert Rev Anticancer Ther. 2019 Jun;19(6):431-435. doi: 10.1080/14737140.2019.1604228. Epub 2019 Apr 14.

DOI:10.1080/14737140.2019.1604228
PMID:30950666
Abstract
摘要

相似文献

1
Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC).转移性表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）的第三代EGFR酪氨酸激酶抑制剂格局
Expert Rev Anticancer Ther. 2019 Jun;19(6):431-435. doi: 10.1080/14737140.2019.1604228. Epub 2019 Apr 14.
2
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.一代 EGFR-TKI 治疗失败的既往治疗的非小细胞肺癌患者中埃非替尼的再挑战。
Cancer Chemother Pharmacol. 2019 May;83(5):817-825. doi: 10.1007/s00280-019-03790-w. Epub 2019 Feb 13.
3
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在一线酪氨酸激酶抑制剂治疗中出现疾病进展时的优化管理。
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
4
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.持续表皮生长因子受体（EGFR）抑制的疗效以及刺猬信号通路（Hedgehog）在具有EGFR激活突变的人肺癌细胞EGFR获得性耐药中的作用
Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.
5
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.阿法替尼用于奥希替尼耐药的EGFR外显子19缺失/T790M/P794L突变的非小细胞肺癌
J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25.
6
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.表皮生长因子受体突变的非小细胞肺癌中的下一代表皮生长因子受体酪氨酸激酶抑制剂
Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8.
7
New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations.新数据凸显了第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）在具有罕见EGFR突变的非小细胞肺癌（NSCLC）患者中的疗效和安全性结果。
Thorac Cancer. 2020 Mar;11(3):495-497. doi: 10.1111/1759-7714.13334. Epub 2020 Jan 28.
8
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.阿法替尼用于非小细胞肺癌一线治疗的临床证据和经验。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808659. doi: 10.1177/1753466618808659.
9
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.分析第三代 EGFR 酪氨酸激酶抑制剂阿维替尼治疗 EGFR T790M 阳性非小细胞肺癌患者的耐药机制：来自 I 期临床试验的结果。
EBioMedicine. 2019 May;43:180-187. doi: 10.1016/j.ebiom.2019.04.030. Epub 2019 Apr 23.
10
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?抗表皮生长因子受体靶向治疗在局部晚期 III 期非小细胞肺癌中的作用：给还是不给？
Curr Oncol Rep. 2019 Aug 13;21(9):84. doi: 10.1007/s11912-019-0835-x.

引用本文的文献

1
Effective neoadjuvant aumolertinib therapy facilitates transformation of unresectable to resectable advanced non‑small cell lung: A case report.有效的新辅助奥莫替尼治疗促进不可切除的晚期非小细胞肺癌转化为可切除：一例报告。
Oncol Lett. 2025 Apr 28;29(6):317. doi: 10.3892/ol.2025.15063. eCollection 2025 Jun.
2
Advanced approaches of developing targeted covalent drugs.开发靶向共价药物的先进方法。
RSC Med Chem. 2022 Oct 11;13(12):1460-1475. doi: 10.1039/d2md00216g. eCollection 2022 Dec 14.
3
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
真实世界中来自中东欧地区的表皮生长因子受体突变型晚期非小细胞肺癌患者的检测实践、治疗模式和临床结局：一项回顾性图表审查研究（REFLECT）。
Curr Oncol. 2022 Aug 17;29(8):5833-5845. doi: 10.3390/curroncol29080460.
4
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.发现 BLU-945，一种针对治疗耐药性非小细胞肺癌的可逆、强效且保留野生型的下一代 EGFR 突变抑制剂。
J Med Chem. 2022 Jul 28;65(14):9662-9677. doi: 10.1021/acs.jmedchem.2c00704. Epub 2022 Jul 15.
5
Cardiac Safety Assessment of Lazertinib: Findings From Patients With Mutation-Positive Advanced NSCLC and Preclinical Studies.拉泽替尼的心脏安全性评估：来自突变阳性晚期非小细胞肺癌患者的研究结果及临床前研究
JTO Clin Res Rep. 2021 Sep 8;2(10):100224. doi: 10.1016/j.jtocrr.2021.100224. eCollection 2021 Oct.
6
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.T790M 阴性 EGFR 突变 NSCLC 的综合分析揭示了广泛的谱系转化和治疗机会。
Clin Cancer Res. 2021 Nov 1;27(21):5939-5950. doi: 10.1158/1078-0432.CCR-20-4607. Epub 2021 Jul 14.
7
Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status.血管生成拟态是肺腺癌无进展生存期的负向指标，与一线治疗和表皮生长因子受体突变状态无关。
BMC Cancer. 2021 Feb 6;21(1):132. doi: 10.1186/s12885-021-07863-z.
8
Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.靶向治疗后晚期非小细胞肺癌的挽救性手术：病例系列研究。
Thorac Cancer. 2020 Apr;11(4):1061-1067. doi: 10.1111/1759-7714.13366. Epub 2020 Feb 28.